We are very pleased to announce the award of a Medical Research Council Industrial CASE Studentship to Professor Kenneth Linton of Queen Mary University of London in collaboration with BioMoti. This prestigious training grant will support a standout PhD student to study the basic cellular and molecular biology mechanisms underpinning ‘targeting cancer cells with CD95R-coated nanoparticles’. Targeted delivery is a promising approach for therapeutic development with the recent clinical trial successes and market launch of Adcetris® by Seattle Genetics and Kadcyla® by Roche highlighting the paradigm shift in the case of antibody-drug conjugates.
Dr Davidson Ateh, CEO of BioMoti, said: ‘This MRC award is hugely welcome and represents the first funded collaborative venture between BioMoti and Prof Linton’s laboratory based on our mutual scientific interests. The complementary expertise in membrane protein biology and bioengineered drug delivery platforms brought by both partners will ensure exciting science is explored and developed in the crucial multidisciplinary area of targeted therapeutics delivery.’
Professor Kenneth Linton, Professor of Protein Biochemistry at Queen Mary University of London, added: ‘We are excited by this new collaborative venture and delighted by the support of the MRC. For many years my group has studied the mechanism by which drug-pumps extrude potential therapeutics from cancer cells, thus preventing them reaching their intracellular targets. These new, targeted, nanoparticles developed by BioMoti, should be capable of circumventing these pumps and it will be interesting to characterise their route of entry and to optimise their uptake into cancer cells’
Click here for a link to Professor Kenneth Linton’s group
Click here for a link to Queen Mary University of London
Click here for a link to the MRC Industrial CASE Studentship scheme
For further information, please contact:
Dr Davidson Ateh
Notes to editors:
BioMoti exists to transform the lives of cancer patients by doing things differently. We seek to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells; aiming to dramatically increase efficacy whilst reducing side effects.
Oncojans™ are a new class of therapeutic microparticles that target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The Oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.
MOTI1001 is BioMoti’s lead Oncojan™ based ovarian cancer candidate that has shown very promising potential in early preclinical studies.